The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure

source extracted confidence: high 2026-04-09
#adult #aged #crataegus #disease-progression #disease-free-survival

The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure

Zick et al., 2008 | Eur J Heart Fail | Rct

Citation

Zick Suzanna M, Gillespie Brenda, Aaronson Keith D. The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail. 2008-Jun;10(6):587-93. doi:10.1016/j.ejheart.2008.04.008

Abstract

AIM: To examine whether hawthorn (Crataegus Special Extract WS 1442 {CSE}) inhibits progression in heart failure (HF) patients. METHODS: We performed a retrospective analysis of data from the HERB CHF study in which patients with mild to moderate HF were randomised to either CSE 900 mg or placebo for 6 months. The primary outcome was time to progression of HF (HF death, hospitalisation, or sustained increase in diuretics) as assessed by log-rank tests and by Cox modelling. RESULTS: Progression of HF occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35: p=0.86). Patients receiving CSE were 3.9 times (95% CI=1.1-13.7: p=0.035) more likely to experience HF progression at baseline. In adjusted analysis, the risk of having early HF progression in the CSE group increased to 6.4 (95% CI=1.5, 26.5: p=0.011). In patients with LVEF< or =35%, those taking CSE were at significantly greater risk (3.2, 95% CI=1.3, 8.3: p=0.02) than the placebo group. CONCLUSIONS: CSE does not reduce heart failure progression in patients who have HF. CSE appears to increase the early risk of HF progression.

Key Findings

Progression of HF occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35: p=0.86). Patients receiving CSE were 3.9 times (95% CI=1.1-13.7: p=0.035) more likely to experience HF progression at baseline. In adjusted analysis, the risk of having early HF progression in the CSE group increased to 6.4 (95% CI=1.5, 26.5: p=0.011). In patients with LVEF< or =35%, those taking CSE were at significantly greater risk (3.2, 95% CI=1.3, 8.3: p=0.02) than the placebo group.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population mild to moderate hf
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Adult
  • Aged
  • Crataegus
  • Disease Progression
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Heart Failure
  • Humans
  • Male
  • Middle Aged
  • Phytotherapy
  • Plant Extracts
  • Retrospective Studies
  • Severity of Illness Index
  • Stroke Volume

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural
  • Vertical: hawthorn

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09